We demonstrate that the fusokine Fβ2 modulates various cell populations, including tumor cells, DCs, MDSCs and CD8+ T cells, leading to the favorable therapeutic outcome after its intratumoral delivery in the form of mRNA. This evidence concerns the gene CD8A and neoplasm.